pharmaceutical industry

See the following -

PLOS & DNDi Launch A New Collection Celebrating A Decade Of Open Access And NTD R&D

Rhona MacDonald | PLOS.org | December 5, 2013

As part of a collaborative initiative, PLOS and the Drugs for Neglected Diseases initiative (DNDi) are delighted to launch a special Collection—PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D—to coincide with a joint event at the Institut Pasteur in Paris celebrating the 10 year anniversary of DNDi... Read More »

Re-Examining The FDA Antibiotics Decision: Banning Growth Promoters Won’t Be Enough

Maryn McKenna | Wired | December 27, 2013

In my first take on the news of the FDA finalizing its request to agriculture to stop using growth-promoter antibiotics, I promised to come back for a more thoughtful reaction. And then this happened, and this happened, and the holidays happened, and, well, it’s been a busy few weeks. Read More »

Re-thinking Clinical Trials For The World Of Crowdsourcing

Laurie Halloran | Xconomy | April 16, 2013

Disruption isn’t a word normally associated with clinical drug development, but nevertheless it is coming. [...] There are signals that drug development is starting to catch up with the general trend toward open collaboration and innovation. This trend is enabling tremendous advances in other industries, so why not ours? Read More »

Richard Smith: Is The Pharmaceutical Industry Like The Mafia?

Richard Smith | BMJ Group | September 10, 2013

There must be plenty of people who shudder when they hear that Peter Gøtzsche will be speaking at a meeting or see his name on the contents list of a journal. He is like the young boy who not only could see that the emperor had no clothes but also said so. [...] Read More »

Rise Of Superbugs Threatens Antibiotic Crisis

Ian Sample | The Guardian | January 24, 2013

Lethal drug-resistant organisms mean threat must be listed on register of civil emergencies, says chief medical officer Read More »

Roche, Medivation, Santen and Biomarin Will Discuss CDISC Implementation Challenges At The Next Silicon Valley BioTalks

Press Release | Clinical Data Interchange Standards Consortium (CDISC) | September 12, 2013

Panel composed of CDISC experts from Roche, Medivation, Santen, Biomarin and Clinovo will discuss and share ideas around the topic: “CDISC for Medical Device Companies: Progress Made and Best Practices from Pharma/Biotech Implementation”. Read More »

Serious Risks and Few New Benefits from FDA-Approved Drugs

Donald W. Light | Health Affairs Blog | July 6, 2015

Over the past year, the U.S. Senate and The New York Times have been investigating the failure of the nation’s auto safety regulators to protect citizens from cars with occasionally dangerous faulty devices. But neither august institution has paid attention to the Food and Drug Administration’s (FDA) failure to protect the 170 million Americans who take prescription drugs from adverse reactions that are killing more than 2,400 people every week. Annually, prescription drugs cause over 81 million adverse reactions and result in 2.7 million hospitalizations...

Read More »

Shield Therapeutics Selects OpenClinica Enterprise

Press Release | Shield Therapeutics®, OpenClinica® | January 4, 2013

OpenClinica, LLC and Shield Therapeutics announces that Shield Therapeutics has selected the OpenClinica Enterprise software for its clinical data management needs related to the company’s clinical trials. [...] Read More »

Stevens Professor Joins Open Source Effort To Develop Low-Cost Drugs

Press Release | Stevens Institute of Technology | March 16, 2013

Professor A.K. Ganguly of the Department of Chemistry, Chemical Biology & Biomedical Engineering at Stevens Institute of Technology is contributing his expertise and passion to the Council of Scientific and Industrial Research (CSIR) Open Source Drug Discovery initiative... Read More »

Sticking It To Big Pharma With Crowdfunded Nanotech

Laura Hood | The Conversation | July 16, 2013

Students at the University of York are challenging what they see as the closed worlds of nanotechnology and healthcare by crowdsourcing funds to produce a new type of treatment for cancer using magnetic nanoparticles. Read More »

Study: Brand Name Drugs Drive Up Medicare Spending

Ankita Rao | The Washington Post | June 11, 2013

A new study suggests that cash-strapped Medicare missed an opportunity to save more than $1 billion by not addressing the varying costs and use of prescription drugs. Read More »

Superbugs Are A 'Costly War We Can't Win': Doctors

Mark Koba | CNBC | April 4, 2013

Germs are perfect machines of evolution. Their ability to mutate and survive attempts (by humans and nature) to destroy them has led to some being called "superbugs." Resistant to existing antibiotics, superbug-related infections worldwide result in thousands of deaths each year—an estimated 99,000 in the U.S. alone for each of the past 10 years. Read More »

Tamiflu Cost Us £424m Yet We Still Don’t Know Much About It

Tom Jefferson | The Conversation | June 3, 2013

Are you worried about how decisions involving public money are made? You should be. Read More »

The $100,000-Per-Year Pill: How US Health Agencies Choose Pharma Over Patients

Fran Quigley | TruthOut | August 5, 2016

Don Reichmuth survived prostate cancer once before, back in 2007, so his physician was concerned when tests recently revealed the cancer had returned. Reichmuth's physician prescribed a drug called enzalutamide, marketed by the Japanese company Astellas Pharma, Inc. under the brand name Xtandi. But when the physician sent the prescription to the pharmacy, the managers of Reichmuth's insurance plan sent back an immediate refusal to approve it. Reichmuth, a retired teacher who lives in Washington State, was puzzled by the logic. Then he learned the price of the Xtandi prescription: over $9,700 each month...